Regional,sex,and age differences in diagnostic testing among participants in the NAVIGATE-ESUS trial

Abstract

Background and aim

The diagnosis of embolic stroke of undetermined source (ESUS) is based on excluding other more likely stroke etiologies, and therefore diagnostic testing plays an especially crucial role. Our objective was to compare the diagnostic testing by region, sex, and age among the participants of NAVIGATE-ESUS trial.

Methods

Participants were grouped according to five global regions (North America, Latin America, Western Europe, Eastern Europe and East Asia), age (<60, 60–74, and >75 years), and sex. Frequencies of each diagnostic test within areas of echocardiography, cardiac rhythm monitoring, and arterial imaging were described and compared across groups. A multivariable logistic regression model for each diagnostic test was fit to assess the independent influence of each of region, age, and sex and likelihood of testing.

Results

We included 6985 patients in the analysis (918 from North America; 746 from Latin America; 2853 from Western Europe; 1118 from Eastern Europe; 1350 from East Asia). Average age (highest in Western Europe (69 years), lowest in Eastern Europe (65 years)), % females (highest in Latin America (44%) and lowest in East Asia (31%)), and use of each diagnostic test varied significantly across regions. Region, but not sex, was independently associated with use of each diagnostic test examined. Transesophageal echocardiography and either CT or MR angiogram were more often used in younger patients.

Conclusion

Diagnostic testing differed by region, and less frequently by age, but not by sex. Our findings reflect the existing variations in global practice in diagnostic testing in ESUS patients.

Keywords

Embolic stroke of undetermined source region age sex

Get full access to this article

View all access options for this article.

References

Hart

Diener

H-C

Coutts

, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13: 429–438.

Gladstone

Spring

Dorian

, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014; 370: 2467–2477.

Wachter

Gröschel

Gelbrich

, et al. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF RANDOMISED): an open-label randomised controlled trial. Lancet Neurol 2017; 16: 282–90.

Sanna

Diener

H-C

Passman

, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370: 2478–2486.

Kamel

Merkler

Iadecola

Gupta

Navi

. Tailoring the approach to embolic stroke of undetermined source. JAMA Neurol 2019; 76: 855–861.

Perera

Vanassche

Bosch

, et al. Embolic strokes of undetermined source: prevalence and patient features in the ESUS Global Registry. Int J Stroke 2016; 11: 526–533.

Kasner

Lavados

Sharma

, et al. Characterization of patients with embolic strokes of undetermined source in the NAVIGATE ESUS randomized trial. J Stroke Cerebrovasc Dis 2018; 27: 1673–1682.

Hart

Sharma

Mundl

, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018; 378: 2191–2201.

Sposato

Cipriano

Saposnik

Vargas

Riccio

Hachinski

. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2015; 14: 377–387.

10.

Witsch

Merkler

Chen

, et al. Incidence of atrial fibrillation in patients with recent ischemic stroke versus matched controls. Stroke 2018; 49: 2529–2531.

11.

Cantú-Brito

Sampaio Silva

Ameriso

. Embolic stroke of undetermined source in Latin America. Neurologist 2017; 22: 171–81.

12.

Katsanos

Bhole

Frogoudaki

, et al. The value of transesophageal echocardiography for embolic strokes of undetermined source. Neurology 2016; 87: 988–995.

13.

Healey

Gladstone

Swaminathan

, et al. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation. JAMA Neurol 2019; 76: 764–773.

14.

Diener

H-C

Sacco

Easton

, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019; 380: 1906–1917.

15.

Singh

Moddy

Panzov

Gladstone

. Carotid intraplaque hemorrhage in patients with embolic stroke of undetermined source. J Stroke Cerebrovasc Dis 2018; 27: 1956–1959.

16.

McDermott

Lisabeth

Baek

, et al. Sex disparity in stroke quality of care in a community-based study. J Stroke Cerebrovasc Dis 2017; 26: 1781–1786.

17.

Perera

Swaminathan

Veltkamp

, et al. Frequency and features of embolic stroke of undetermined source in young adults. Eur Stroke J 2018; 3: 110–116.

18.

Cantú-Brito

Ruiz-Sandoval

Murillo-Bonilla

, et al. The first Mexican multicenter register on ischaemic stroke (The PREMIER Study): demographics, risk factors and outcome. Int J Stroke 2011; 6: 93–94.

19.

Rothwell

Algra

Chen

, et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 2016; 388: 365–375.

20.

Perera KS, Ng KKH, Nayar S, et al. Association between low-dose Rivaroxaban with or without aspirin and ischemic stroke subtypes: A Secondary Analysis of the COMPASS Trial. JAMA Neurol 2019 Sep 16. DOI: 10.1001/jamaneurol.2019.2984.

21.

Ntaios

Georgiopoulos

Perlepe

, et al. A tool to identify patients with embolic stroke of undetermined source at high recurrence risk. Neurology 2019 (in press).

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.33 MB